From Data to Decisions: New Directions in Antiretroviral Therapy Post CROI 2026

Needs Assessment

Rapid advances in HIV disease management require the ongoing attention of clinicians involved in direct patient care. Clinicians must continually adapt to evolving data on ART, including new agents, emerging treatment strategies, and important findings presented at major scientific meetings such as CROI. As treatment options expand, providers may face challenges in selecting and optimizing ART regimens, integrating new therapies into clinical practice, and making informed treatment decisions for individuals who are treatment-naive or treatment-experienced. This course will address the clinical implications of this new data in HIV and treatment. Information will be presented through a mix of didactic presentations, clinically relevant cases, and interactive discussions led by an expert faculty of HIV clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing ART in different clinical circumstances
• List drugs for selecting initial ART therapy, including the role of newly approved in clinical practice
• Apply practical strategies for screening, detecting, and managing hepatitis B virus in people with HIV in the era of 2-drug antiretroviral therapy
• Interpret genotypic resistance testing and evaluate approaches to simplifying ART in the setting of drug resistance
• Identify key clinical considerations in the management of advanced HIV disease, including tuberculosis, cryptococcosis, and other opportunistic infections

Preliminary Topics

• Initial antiretroviral therapy: integrating newly approved agents into clinical practice
• Hepatitis B in the era of 2-drug HIV therapy: screening, detection, and clinical management
• Simplifying antiretroviral therapy in the setting of drug resistance
• Management of advanced HIV disease: tuberculosis, cryptococcosis, and other opportunistic infections

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 7 or more days before the date of an activity to receive a refund minus a $15 administrative fee. Any requests made within 6 days before the course will not be refunded. Please note: registration substitutions are not permitted.